Anzeige
Mehr »
Login
Dienstag, 07.05.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
+56,25% in 5 Tagen: Genialer Schachzug - diese Übernahme verändert alles
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
52 Leser
Artikel bewerten:
(0)

Ultroz Elite Wearable Ultrasonic Therapy System was Named as Finalist in the 2013 Medical Design Excellence Awards

TRUMBULL, Conn., April 2, 2013 /PRNewswire/ --ZetrOZ, Inc. (www.zetroz.com) announced today that its Ultroz Elite Wearable Ultrasonic Therapy System has been selected as a finalist in the 15th Annual Medical Design Excellence Awards competition. The Ultroz Elite Wearable Ultrasonic Therapy System is the first of its kind - a miniaturized therapeutic ultrasound system designed and engineered to reduce swelling, relieve pain, speed healing and enhance athletic performance. The device is about the size of an ipod and can be worn during normal activity. The Ultroz Elite is recommended by top Equine veterinarians and physical therapists worldwide. ZetrOZ, Inc. is currently awaiting FDA approval and CE mark for the human version of its wearable ultrasound therapy system.

(Photo: http://photos.prnewswire.com/prnh/20130402/NY87686 )

The Medical Design Excellence Awards (www.MDEAwards.com) are the industry's premier design awards competition and is the only awards program exclusively recognizing contributions and advances in the design of medical products. Entries are evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions improving healthcare delivery and changing traditional medical attitudes or practices, features providing enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so the product meets its clinical objectives.

A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics.

"We are honored to be recognized by the MDEA judges," said Bryant Guffey, CEO of ZetrOZ, Inc. "The widespread adoption of our wearable ultrasound systems in the medical veterinary community and on top equine athletes has been a fantastic and rewarding experience. We're looking forward to introducing the product for human use later this year."

Finalists in each of the competition's ten categories were officially announced in the April issue of Medical Device and Diagnostic Industry (www.mddionline.com) magazine. The winners will be announced on June 19, 2013, during a cocktail reception starting at 4:30 pm at the Marriott Hotel in downtown Philadelphia. The ceremony will be held in conjunction with the 30th MD&M East event (www.MDMEast.com) at the Pennsylvania Convention Center, June 19, 2013. MDEA-winning products will be honored at the ceremony with Bronze, Silver, or Gold-level awards in each category. One Gold-winning product will be awarded 'Best-in-Show'.

The Medical Design Excellence Awards are underwritten and presented by UBM Canon, the global advanced manufacturing and MedTech authority, and by Medical Device and Diagnostic Industry (MD+DI), the industry's central source for late breaking news, information, and business intelligence.

For more information about the Medical Design Excellence Awards, visit www.MDEAwards.com, or e-mail mdea@ubm.com.

Media Contact:
JoAnne Guarino
888-202-9831
jguarino@zetroz.com

SOURCE ZetrOZ, Inc.

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.